The week in pharma: action, reaction and insight – week to March 8, 2024
By Barbara Obstoj-Cardwell. Editor
Germany’s Bayer has entered into deal with USA-based BridgeBio Pharma to commercialize its cardiovascular candidate acoramidis worth $310 million in upfront and milestone payments. Research news last week included Denmark’s Novo Nordisk releasing positive new data on its semaglutide, showing it cut kidney-disease related events in diabetes patients by 24%. Also, Singapore-based TauRx Pharma released new data on its Alzheimer’s candidate hydromethylthionine mesylate (HMTM). US President Joe Biden is moving further with his intent to bring down drug prices in the USA, with plans not to limit Medicare negotiations to just 20 drugs a year.
Bayer deal bolsters BridgeBio’s EU commercial position and balance sheet
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze